H.B. Fuller Q2 2026 slides: strong results, £715M medical deal

H.B. Fuller reported Q2 2026 adjusted EPS of $1.41 and revenue of $950.3 million, with adjusted EBITDA up 9% to $181 million and operating cash flow hitting a Q2 record of $121 million. The company raised full-year 2026 guidance for adjusted EBITDA to $650 million-$675 million and EPS to $4.60-$4.90, but shares fell 8.2% after hours as investors focused on the £715 million Advanced Medical Solutions acquisition and the resulting leverage increase to about 4.0x net debt/EBITDA at closing. The deal expands H.B. Fuller’s medical exposure and could add about $55 million in run-rate synergies, but integration and balance-sheet risk temper near-term sentiment.

Analysis

FUL’s print is less about a one-quarter beat and more about the market re-rating the balance sheet risk embedded in a transformation story. The key second-order issue is that management is choosing to spend operating credibility on an acquisition just as the underlying business is entering a tougher mix: low-single-digit organic growth, weaker consumer volumes, and higher input costs. That combination usually compresses multiple expansion for a few quarters because investors stop capitalizing near-term margin discipline and start discounting execution risk.

The real winner here may be AMS, but only if the deal closes and integration is clean. The acquisition gives FUL a credible path into a structurally better end market, yet the financing structure means equity holders are underwriting a levered call option on synergy capture and deleveraging. If synergies slip by even 20%-30%, the implied payback stretches meaningfully and the market will likely keep the stock capped until leverage is visibly trending back toward the target band.

From a competitive standpoint, this is mildly negative for smaller adhesive/medical platform players that compete on scale and customer access, because FUL can now cross-sell through a larger channel and potentially bid more aggressively for niche assets. The hidden risk is internal distraction: running Quantum Leap and a cross-border medical integration simultaneously raises the probability of temporary service issues or procurement slippage, which could hand share to rivals in packaging and industrial adhesives over the next 2-3 quarters.

The contrarian take is that the selloff may overstate permanent equity damage if the company truly can fund the deal, deliver $55 million of synergies, and de-lever within 24 months. That said, the market is unlikely to give credit for the strategic mix shift until it sees at least one quarter of post-close synergy run-rate and no deterioration in working capital or free cash flow conversion. In other words, the stock is likely range-bound until there is evidence the company can do M&A without sacrificing the core business.

Key Decisions for Investors

• Short-term: fade the post-earnings bounce in FUL via a 30-60 day tactical short or put spread if shares retrace toward pre-gap levels; risk/reward is attractive while leverage and integration headlines dominate sentiment.
• Medium-term: initiate a pair trade long AMS / short FUL where available or synthetically via options, betting the target captures deal premium while the acquirer absorbs execution risk over the next 2-3 months.
• For event-driven desks: buy FUL downside protection into any approval/financing volatility; the cleanest hedge is a 3-6 month put spread targeting the period just before expected closing, when leverage concerns should peak.
• For fundamental investors: wait for the first post-close quarter before committing long FUL; require evidence of flat-to-improving free cash flow and management’s ability to keep net leverage on a visible glide path below 3.5x within two quarters.
• Relative-value idea: overweight broader healthcare tools/materials exposure versus FUL until the market assigns credit for the medical segment; the stock is likely to underperform higher-quality compounders while integration uncertainty suppresses multiple expansion.